标签: 标签: 标签: 标签

Same author

A quantitative rapid test for urine creatinine <i>via</i> Fenton's reaction and a self-driven microfluidic device.

Lab on a chip·2026

Same author

A microfluidic microspheres accumulation platform for direct visualization of urine albumin-to-creatinine ratio in patients with chronic kidney disease.

Biosensors & bioelectronics·2026

Same author

Universal Exit-Site Antibiotic Prophylaxis Reduces Exit-Site Infections in Pediatric Peritoneal Dialysis.

Kidney international reports·2025

Same author

Kidney Disease: Improving Global Outcomes Summit Recommendations on Implementation of Diabetes Management in CKD: From Primary to Data-Driven Collaborative Care.

Kidney international reports·2025

Same author

Toxic microbiome and progression of chronic kidney disease: insights from a longitudinal CKD-microbiome study.

Gut·2025

Same author

Fluoroscopic repositioning of Tenckhoff catheter.

Kidney international·2025

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

相关实验视频

标签: 标签: 标签: 标签

相关概念视频

A quantitative rapid test for urine creatinine <i>via</i> Fenton's reaction and a self-driven microfluidic device.

A microfluidic microspheres accumulation platform for direct visualization of urine albumin-to-creatinine ratio in patients with chronic kidney disease.

Universal Exit-Site Antibiotic Prophylaxis Reduces Exit-Site Infections in Pediatric Peritoneal Dialysis.

Kidney Disease: Improving Global Outcomes Summit Recommendations on Implementation of Diabetes Management in CKD: From Primary to Data-Driven Collaborative Care.

Toxic microbiome and progression of chronic kidney disease: insights from a longitudinal CKD-microbiome study.

Fluoroscopic repositioning of Tenckhoff catheter.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

相关实验视频

标签: 标签: 标签: 标签

相关概念视频

相关文章

A quantitative rapid test for urine creatinine <i>via</i> Fenton's reaction and a self-driven microfluidic device.

A microfluidic microspheres accumulation platform for direct visualization of urine albumin-to-creatinine ratio in patients with chronic kidney disease.

Universal Exit-Site Antibiotic Prophylaxis Reduces Exit-Site Infections in Pediatric Peritoneal Dialysis.

Kidney Disease: Improving Global Outcomes Summit Recommendations on Implementation of Diabetes Management in CKD: From Primary to Data-Driven Collaborative Care.

Toxic microbiome and progression of chronic kidney disease: insights from a longitudinal CKD-microbiome study.

Fluoroscopic repositioning of Tenckhoff catheter.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.